Article Text

Download PDFPDF

283 The impact of charlson’s comorbidity index in overall survival for advanced epithelial ovarian cancer
  1. R Nunes1,
  2. H Mantoan1,
  3. B Goncalves1,
  4. C Faloppa1,
  5. L Kumagai1,
  6. L Badiglian-Filho1,
  7. L de Brot2,
  8. A da Costa3 and
  9. G Baiocchi1
  1. 1AC Camargo Cancer Center, Gynecologic Oncology, Sao Paulo, Brazil
  2. 2AC Camargo Cancer Center, Pathology, Sao Paulo, Brazil
  3. 3AC Camargo Cancer Center, Medical Oncology, Sao Paulo, Brazil


Objectives To evaluate the impact of Charlson’s Comorbidity Index (CCI) in overall survival of advanced epithelial ovarian cancer.

Methods We retrospectively analyzed a series of 82 patients with advanced epithelial ovarian cancer (Stages IIIA-IV) from 2009 to 2015. Clinical and pathological variables were extracted from medical-records. Patients were categorized according to CCI in 3 groups: low (0–1), intermediate (2–3) and high (≥4).

Results The median age was 57 years and 62(78.5%) were high-grade serous tumors. Forty-five (54.9%) cases had primary cytoreductive surgery, 33(40.2%) interval cytoreduction and 4(4.9%) staging surgery. Five (6%) patients had stages IIIA-IIIB tumors, 64(78%) stage IIIC and 13(15.8%) stage IV. Sixty-one (75.3%) cases had no residual disease after cytoreduction and 10(12.3%) residual disease ≤1cm. The median Surgical Complexity Score (SCS) was 6 (0–15) and 11 cases (14.7%) had major complications (NCI grade ≥3), including 3(3.6%) deaths within 30 days after surgery. The CCI were low, intermediate and high in 38(46.9%), 36(44.4%) and 7(8.6%) cases, respectively. Notably, CCI was not related to major complications (p=0.3). The median OS and PFS were 70.5 and 20.2 months. The median OS for patients with low, intermediate and high CCIs were 91.8, 51.6 and 38.9 months, respectively (p=0.11). However, CCI impacted PFS, as median PFS for patients with low, intermediate and high CCIs were 32.1, 16.2 and 13.4 months, respectively (p=0.004). Moreover, major complications negatively impacted OS compared to minor complications (91.8 vs.22.1; p=0.002), but not PFS (20.2 vs.22.2; p=0.71).

Conclusions Our data suggest that higher CCI negatively impacted PFS in advanced ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.